(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
A definitive Manual for Picking Electric Vehicle: Decision in favor of Your Number one - 2Marvel's X-Men are joining the battle in 'Avengers: Doomsday': Watch the teaser
- 3Savvy Watches: Which One Is Appropriate for You?
- 4Hundreds of Gazans evacuated from Strip for medical treatment - COGAT
- 5RFK Jr.’s vaccine advisers plan biggest change yet to childhood schedule
- How will the universe end?
- Guinea-Bissau's coup called a 'sham' by West African political figures
- Deadly heat worldwide prompts $300 million for climate health research at COP30
- Terminal cancer diagnosis announced by JFK's granddaughter
- Lower-cost space missions like NASA's ESCAPADE are starting to deliver exciting science – but at a price in risk and trade‑offs
- Most loved Occasion Dish: What Makes Your Merry Table?
- How did life begin on Earth? New experiments support 'RNA world' hypothesis
- Nitty gritty Manual for Picking Agreeable Tennis shoes
- Criminal Guard Lawyer Expenses: What Would it be advisable for you to Hope to Pay?
